A new treatment combination for pancreatic cancer has produced encouraging results in an early clinical trial, with tumours shrinking or becoming undetectable in some patients.

Researchers tested daraxonrasib alongside chemotherapy in 61 people recently diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

The results were promising. Tumours stopped growing in around 90% of participants, while just over 60% experienced tumour shrinkage or disappearance. In approximately 8% of patients, the cancer became undetectable on CT scans.

Pancreatic cancer remains one of the most difficult cancers to treat. It is often diagnosed at an advanced stage, when treatment options are limited and survival rates remain low.

Daraxonrasib works by targeting RAS-related cancer-driving mechanisms, which play a major role in the growth of many pancreatic tumours. Scientists hope targeted treatments may offer better disease control than conventional approaches alone.

However, doctors caution that the findings do not mean the cancer has been cured. Patients were followed for an average of around 18 months, and researchers still need to establish how long the response lasts, whether the disease returns and whether treatment can improve long-term survival.

The findings have nevertheless raised optimism in the cancer research community. For a disease that has seen relatively limited progress over decades, the possibility of more effective targeted treatment could represent an important step forward.

Further studies will determine whether the early results translate into lasting benefits for patients.